Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begin in 2028.